Alnylam Pharmace. buy Needham & Company LLC
Summary
This prediction is currently active. The prediction for Alnylam Pharmace. disappoints with a performance of -14.58%. This prediction currently runs until 04.08.24. The prediction end date can be changed by Needham___Company_LL at any time. Needham___Company_LL has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Alnylam Pharmace. | 2.804% | 2.804% |
iShares Core DAX® | -2.023% | -3.140% |
iShares Nasdaq 100 | 4.625% | 8.753% |
iShares Nikkei 225® | -2.088% | -0.980% |
iShares S&P 500 | 2.398% | 4.677% |
Comments by Needham___Company_LL for this prediction
In the thread Alnylam Pharmace. diskutieren
Stopped prediction by Needham___Company_LL for Alnylam Pharmace.
Alnylam Pharmace.
12.09.23
12.09.24
18:21